[III-JCKAP7-1-6] Single tertiary center experience using Gore Cardioform Atrial Septal Defect Occluder for secundum atrial septal defect closure in children
キーワード：atrial septal defect, device, nterventional cardiac catheterization
Objective: To evaluate the GORE Cardioform ASD Occluder (GCA)(WL Gore & Associates) device for closure of ostium secundum atrial septal defects (ASDs).
Methods: Between September 2021 and December 2023, 65 children underwent transcatheter ASD closure at our Institution. All patients evaluated by a transesophageal echocardiogram (TEE) for ASD occlusion were included and rims less than 5 mm were defined as deficient, respectively. Procedure results and midterm outcomes are reported.
Results: 59 (91%) cases had successful ASD device closure with GCA, and 6 cases had been treated with other ASD devices. Patients' age and weight were 8.1 ± 3.2 years and 25 ± 9.1 kg, respectively. The diameter of ASD, aortic rim, posterior rim, and IVC rim were 15 ± 4.1 mm, 3.9 ± 3.6 mm, 11 ± 4.6 mm, and 12 ± 5.3 mm, respectively. Aortic rim, posterior rim, and IVC rim deficient were noted in 44 of 58 (76%), 8 (14%), and 7 (12%). One patient who underwent 37mm GCA device deployment, needed elective surgery due to device embolization. Minor complication, transient AV dissociation was recorded in 1 patient. No patient had clinically significant new arrhythmia. Complete closure at acquired at the 6-month follow-up evaluation. Wireframe fracture rate at the 6-month examination was 24%, without clinical and instrumental consequences.
Conclusions: Percutaneous treatment with GCA device is effective and safe in a high percentage of ASD children.
Methods: Between September 2021 and December 2023, 65 children underwent transcatheter ASD closure at our Institution. All patients evaluated by a transesophageal echocardiogram (TEE) for ASD occlusion were included and rims less than 5 mm were defined as deficient, respectively. Procedure results and midterm outcomes are reported.
Results: 59 (91%) cases had successful ASD device closure with GCA, and 6 cases had been treated with other ASD devices. Patients' age and weight were 8.1 ± 3.2 years and 25 ± 9.1 kg, respectively. The diameter of ASD, aortic rim, posterior rim, and IVC rim were 15 ± 4.1 mm, 3.9 ± 3.6 mm, 11 ± 4.6 mm, and 12 ± 5.3 mm, respectively. Aortic rim, posterior rim, and IVC rim deficient were noted in 44 of 58 (76%), 8 (14%), and 7 (12%). One patient who underwent 37mm GCA device deployment, needed elective surgery due to device embolization. Minor complication, transient AV dissociation was recorded in 1 patient. No patient had clinically significant new arrhythmia. Complete closure at acquired at the 6-month follow-up evaluation. Wireframe fracture rate at the 6-month examination was 24%, without clinical and instrumental consequences.
Conclusions: Percutaneous treatment with GCA device is effective and safe in a high percentage of ASD children.